Get the Stockscreener App
3.67
6.14%
-0.24
After Hours:
3.59
-0.08
-2.18%
Scynexis Inc stock is traded at $3.67, with a volume of 188.85K.
It is down -6.14% in the last 24 hours and down -10.71% over the past month.
SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.
See More
Previous Close:
$3.91
Open:
$3.87
24h Volume:
188.85K
Relative Volume:
1.26
Market Cap:
$36.52M
Revenue:
$20.34M
Net Income/Loss:
$-24.52M
P/E Ratio:
-1.0263
EPS:
-3.5761
Net Cash Flow:
$-5.92M
1W Performance:
-10.05%
1M Performance:
-10.71%
6M Performance:
-56.31%
1Y Performance:
-42.66%
1-Day Range:
$3.535
$3.88
1-Week Range:
$3.535
$4.15
52-Week Range:
$3.53
$9.12
Scynexis Inc Stock (SCYX) Company Profile
Name
Scynexis Inc
Sector
Phone
201-884-5485
Address
1 EVERTRUST PLAZA, JERSEY CITY, NJ
Compare SCYX vs TAK, TEVA, HLN, ZTS, UTHR
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SCYX
Scynexis Inc
|
3.67 | 36.52M | 20.34M | -24.52M | -5.92M | -3.5761 |
TAK
Takeda Pharmaceutical Co Adr
|
19.67 | 62.84B | 29.91B | 1.30B | 3.49B | 0.4056 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
41.50 | 48.40B | 17.53B | 1.58B | 444.18M | 1.3457 |
HLN
Haleon Plc Adr
|
10.13 | 44.55B | 14.54B | 2.22B | 2.58B | 0.4871 |
ZTS
Zoetis Inc
|
79.38 | 32.80B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
533.12 | 22.87B | 3.17B | 1.29B | 1.01B | 27.09 |
Scynexis Inc Stock (SCYX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-22-21 | Initiated | Guggenheim | Buy |
| Jan-06-21 | Initiated | Cantor Fitzgerald | Overweight |
| Jul-11-18 | Upgrade | Needham | Hold → Buy |
| Jun-27-18 | Initiated | Maxim Group | Buy |
| Oct-24-17 | Initiated | Guggenheim | Buy |
| Jul-10-17 | Initiated | ROTH Capital | Buy |
| May-09-17 | Downgrade | Needham | Buy → Hold |
| Mar-03-17 | Reiterated | RBC Capital Mkts | Outperform |
| Oct-20-16 | Initiated | H.C. Wainwright | Buy |
| Oct-07-16 | Upgrade | WBB Securities | Buy → Strong Buy |
| Oct-03-16 | Resumed | Brean Capital | Buy |
| Aug-17-16 | Initiated | Guggenheim | Buy |
| Aug-09-16 | Reiterated | Needham | Buy |
| Aug-09-16 | Upgrade | WBB Securities | Speculative Buy → Buy |
| Mar-28-16 | Initiated | Brean Capital | Buy |
| Dec-29-15 | Initiated | WBB Securities | Speculative Buy |
| Nov-16-15 | Reiterated | RBC Capital Mkts | Outperform |
| Jun-10-15 | Initiated | Needham | Buy |
| May-29-14 | Initiated | Canaccord Genuity | Buy |
| May-29-14 | Initiated | RBC Capital Mkts | Outperform |
View All
Scynexis Inc Stock (SCYX) Latest News
SCYNEXIS completes phase 1 study of SCY-770 for kidney disease - Investing.com Nigeria
SCYNEXIS completes phase 1 study of SCY-770 for kidney disease - Investing.com
SCYNEXIS (SCYX) Completes Phase 1 Trial for SCY-770 Targeting AD - GuruFocus
SCYNEXIS completes phase 1 study of SCY-770 for kidney disease - Investing.com Canada
SCYNEXIS Announces Positive Phase 1 Results for SCY-770 in ADPKD, Supports Planned Phase 2 Study in Q4 2026 - Quiver Quantitative
SCYNEXIS Announces Positive Phase 1 Results for SCY-770 in ADPKD, Supports Planned Phase 2 Study in Q4 2026 - Quiver Quantitative
An experimental kidney disease drug was well tolerated in 25 healthy adults - Stock Titan
SCYNEXIS (NasdaqCM:SCYX) Stock Forecast & Analyst Predictions - Simply Wall Street
Stock splits calendar for: - Yahoo Finance UK
Scynexis secures up to USD 214m in BARDA funding for antifungal SCY-247 - AllSci
Scynexis wins BARDA contract worth up to $214 million for antifungal SCY-247 - The Pharma Letter
SCYNEXIS Secures BARDA Funding for Antifungal Pipeline - TipRanks
SCYNEXIS Inc. (SCYX) Stock Price | Live Quotes & Charts | NASDAQ - timothysykes.com
SCYNEXIS Inc. (SCYX) Stock Price | Live Quotes & Charts | NASDAQ - timothysykes.com
SCYNEXIS Inc. (SCYX) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Scynexis stock surges on $214M BARDA contract for SCY-247 - Yahoo Finance
Scynexis stock surges on $214M BARDA contract for SCY-247 - Investing.com
SCYX Stock Draws Trader Focus As New CFO And ADPKD Pivot Take Shape - timothysykes.com
SCYX Stock Draws Traders As Leadership And Kidney Pivot Advance - StocksToTrade
SCYNEXIS Wins BARDA Contract Worth Up to $214 Million for SCY-247 - citybiz
SCYNEXIS secures BARDA contract for antifungal development - Investing.com
Scynexis Shares Rise 13.9% After BARDA Awards SCY-247 Development Contract - Yahoo Finance
Why is Scynexis stock surging today? By Investing.com - Investing.com South Africa
Why is Scynexis stock surging today? By Investing.com - Investing.com Canada
Why is Scynexis stock surging today? - Investing.com
SCYNEXIS secures BARDA contract for antifungal development By Investing.com - Investing.com India
A U.S. health agency could provide up to about $214 million to develop an antifungal treatment if all options are exercised. - Stock Titan
Stocktwits Pharma Pulse: Lilly, Novo Lead A Busy Week — Here Are The Stocks And Readouts To Watch - TradingView
SCYNEXIS, Inc. (SCYX) Stock Price, News, Quote & History - Yahoo! Finance Canada
SCYNEXIS, Inc. Announces Appointment of Steven K. Burke, M.D. to its Board of Directors, Effective September 18, 2026 - marketscreener.com
Scynexis appoints Steven Burke to board of directors - Investing.com
Scynexis (NASDAQ: SCYX) adds kidney drug specialist to its board - Stock Titan
SCYNEXIS Appoints Seasoned Industry Veteran Steven K. Burke, M.D., to its Board of Directors - manilatimes.net
SCYNEXIS Appoints Seasoned Industry Veteran Steven K. Burke, M.D., to its Board of Directors - marketscreener.com
SCYNEXIS Appoints Seasoned Industry Veteran Steven K. Burke, M.D., to its Board of Directors - Stock Titan
Press Release: SCYNEXIS Appoints Seasoned Industry Veteran Steven K. Burke, M.D., to Its Board of Directors - Moomoo
SCYXPhase II ADPKD Catalyst Will Define Long-Term Potential For This Orphan Kidney Therapy - Simply Wall Street
SCYNEXIS (Nasdaq:SCYX)Stock Analysis - Simply Wall Street
Scynexis appoints Todd Minga as senior VP of R&D - Investing.com
A kidney specialist joins SCYNEXIS to lead rare-disease research - Stock Titan
SCYNEXIS Inc Extraordinary Shareholders Meeting Transcript - GuruFocus
SCYNEXIS at Cantor healthcare conference: rare-disease push takes shape By Investing.com - Investing.com South Africa
Scynexis (SCYX) awards CFO 100,000 stock options vesting over 4 years - Stock Titan
New Scynexis (SCYX) CFO reports no company shares - Stock Titan
SCYNEXIS at Cantor healthcare conference: rare-disease push takes shape By Investing.com - Investing.com Nigeria
SCYNEXIS INC (NASDAQ: SCYX) Appoints Sanjay Subramanian as CFO with $500,000 Annual Salary - Kalkine Media
SCYX: Phase II trial of SCY-770 for ADPKD to launch by year-end, targeting major unmet need - TradingView
SCYX: Phase II trial of SCY-770 for ADPKD to launch by year-end, targeting major unmet need - TradingView
SCYNEXIS at Cantor healthcare conference: rare-disease push takes shape - Investing.com
SCYNEXIS at Cantor healthcare conference: rare-disease push takes shape By Investing.com - Investing.com India
Scynexis Inc Stock (SCYX) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.08%
1.49%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):